Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
Read original at benzingaStocks · News reference
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 4:31 PM
- Checked
- Aug 14, 2026, 4:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
Read original at benzingaFate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated regulatory pathway
Read original at benzinga